Drug delivery to target the posterior segment of the eye;Vectorisation intra-oculaire

Medecine/Sciences

Volumn 20, Issue 6-7, 2004, Pages 701-706

  Behar Cohen, Francine ^a,b  

^a INSERM   (France)

^b Fondation Ophtalmologique de Rothschild   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; NANOPARTICLE;

CONTROLLED DRUG RELEASE; DEVELOPED COUNTRY; DEVICE; DRUG DELIVERY SYSTEM; IONTOPHORESIS; OSMOTIC PUMP; POSTERIOR EYE CHAMBER; RETINA DISEASE; REVIEW; VISUAL DISORDER;

EID: 3142657617     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2004206-7701     Document Type: Review

References (43)

1. Reichel E, Berrocal A, Ip M, et al. Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology 1999; 106: 1908-14.
2. Schmidt-Refurth U, Miller J, Sickenberg M, et al. Photodynamic therapy with verteprofin for choroidal neovascularization cauzed by age-related macular degeneration. Arch Ophthalmol 1999; 117: 1177-87.
3. Hauswirth WW, Lewin AS. Ribozyme uses in retinal gene therapy. Prog Retin Eye Res 2000; 19: 689-710.
4. Acland GM, Aguire GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28: 92-5.
5. Liang FQ, Dejneka NS, Cohen DR, et al. Aav-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse. Mol Ther 2001; 3: 241-8.
6. Ferrara N, Alitala K. Clinical applications of angiogenic growth factors and their inhibitors. Nature Med 1999; 5: 1359-64.
7. Nir I, Kedzierski W, Chen J, Travis GH. Expression of Bcl-2 protects against photoreceptor degeneration in retinal degeneration slow (rds) mice. J Neurosci 2000; 15: 2150-4.
8. Frasson M, Sahel JA, Fabre M, et al. Retinitis pigmentosa: Rod photoreceptor rescue by a calcium-channel blocker in the rd mouse. Nature Med 1999; 5: 1183-7.
9. Maurice D, Mishima S. Ocular pharmacokinetics in ML. In: Sears ML, ed. Pharmacology of the eye. Berlin: Springer-Verlag, 1984: 19-116.
10. Tojo K, Isowaki A. Pharmacokinetic model for in vivo/in vitro correlation of intravitreal drug delivery. Advanced Drug Delivery Rev 2001; 52: 17-24.
11. Weijtens O, van der Sluijs FA, Schoemaker RC, et al. Peribulbar corticosteroids injection: Vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am J Ophthalmol 1997; 123: 358-63.
12. Bodker FS, Ticho BH, Feist RM, Lam TT. Intraocular dexamethasone penetration via subconjunctival or retrobulbar injections in rabbits. Ophthalmic Surg 1993; 24: 453-7.
13. Blair NP, Evans MA, Lesar TS, Zeimer RC. Fluorescein and fluorescein glucuronide pharmacokinetics after intravenous injection. Invest Ophthalmol Vis Sci 1986; 27: 1107-14.
14. Araie M, Maurice DM. The loss of fluorescein, fluorescein glucuronide and fluorescein isathiocyanate dextran from the vitreous by the anterior and retinal pathways. Exp Eye Res 1991; 52: 27-39.
15. Martin DF, Parks DJ, Mellow SO, et al. Treatment of CMV retinitis with an intraocular sustained-release ganciclovir implant: A randomized controlled clinical trial. Arch Ophthalmol 1994; 112: 1531-9.
16. Jaffe G, Ben-Nun J, Guo H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000; 11: 2024-33.
17. Kimura H, Ogura Y, Hashizoe M, et al. A new vitreal drug delivery system using an implantable biodegradable polymeric device. Invest Ophthalmol Vis Sci 1994; 35: 2815-9.
18. Kunou N, Ogura Y, Yasukawa T, et al. Long term sustained release of GC from biodegradable scleral implant for the treatment of CMV retinitis. J Control Release 2000; 10: 263-71.
19. Hashizoe M, Ogura Y, Takanashi T, et al. Implantable biodegradable polymeric device in the treatment of experimental proliferative vitreoretinopathy. Curr Eye Res 1995; 14: 473-7.
20. Kunou N, Ogura Y, Honda Y, et al. Biodegradable scleral implant for controlled intraocular delivery of betamethasone phosphate. Int J Biomat Res 2000; 51: 634-41.
21. Peyman GA, Yang D, Khoobehi B, et al. In vitro evaluation of polymeric matrix and porous biodegradable reservoir devices for slow-release drug delivery. Ophthalmic Surg and lasers 1996; 27: 384-91.
22. Chasin M, Domb A, Ron E, et al. Polyanhydrides as drug delivery systems. In: Chasin M, Langer R, eds. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker, 1990: 43-70.
23. Heller J, Barr J, Shen H, et al. Poly(ortho esters)-their development and some recent applications. Eur J Pharm Biopharm 2000; 50: 121-8.
24. Behar-Cohen F, BenEzra D, Einmahl S, Gurny R. Challenge of intraocular dug delivery. Eur J Pharm Rev 2001; 6: 35-40.
25. Einmahl S, Capancioni S, Schwach-Abdellaoui K, et al. Therapeutic applications of viscous and injectable poly(ortho) esters. Adv Drug Deliv Rev 2001; 53: 45-73.
26. Einmahl S, Behar-Cohen F, Tabatabay C, et al. A viscous bioerodible poly(ortho ester) as a new biomaterial for intraocular application. J Biomed Mater Res 2000; 5: 566-73.
27. Einmahl S, Behar-Cohen F, D'Hermies F, et al. A new poly(ortho ester)-based drug delivery system for the adjunct treatment of filtering surgery. Invest Ophthalmol Vis Sci 2000; 42: 695-700.
28. Einmahl S, Savoldelli M, D'Hermies F, et al. Evaluation of a new biomaterial in the suprachoroidal space. Invest Ophthalmol Vis Sci 2002; 43: 1533-9.
29. Sakurai E, Ozeki H, Kunou N, Ogura Y. Effect of particle size of polymeric nanospheres on intravitreous kinetics. Ophthalmic Res 2001; 33: 31-6.
30. Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactides nanoparticles. Invest Ophthalmol Vis Sci 2003; 44: 3562-9.
31. Peyman G, Convay M, Khoobei B, Soike K. Clearance of of microsphere-entrapped 5-FU and cytosine arabinoside from the vitreous of primate. Int Ophthalmol 1992; 16: 109-13.
32. Moritera T, Ogura Y, Yoshimura N, et al. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreo retinopathy. Invest Ophthalmol Vis Sci 1992; 33: 3125-30.
33. Akula SK, Ma PE, Peyman GA, et al. Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. Br J Ophthalmol 1994; 78: 677-80.
34. Bochot A, Fattal E, Boutet V, et al. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci 2002; 43: 253-9.
35. Barza M, Stuart M, Szoka F, Jr. Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes. Invest Ophthalmol Vis Sci 1987; 28: 893-900.
36. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci 2000; 41: 1181-5.
37. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 2001; 52: 37-48.
38. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci 2000; 41: 1186-91.
39. Behar-Cohen F, Parel JM, El Aouni A, Chauvaud D. Iontophoresis: The past and the future. J Fr Ophthalmol 2001; 24: 319-27.
40. Voigt M, de Kozak Y, Halhal M, et al. Down regulation of NOSII gene expression by iontophoresis of anti-sense oligonucleotide in endotoxin-induced uveitis. Biochem Biophys Res Comm 2002; 295: 336-41.
41. Lam TT, Fu J, Tso MO. A histopathological study of retinal lesions inflicted by transscleral iontophoresis Graefe's Arch Clin Exp Ophthalmol 1991; 229: 389-94.
42. Behar-Cohen FF, El Aouni A, Gautier S, et al. Transscleral coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: Influence of duration of treatment, current intensity and drug concentration in ocular tissues and fluids levels. Exp Eye Res 2002; 74: 51-9.
43. Halhal M, Renard G, Courtois Y, et al. Iontophoresis from the lab to the bedside. Exp Eye Res 2004; 78: 751-7.